國家衛生研究院 NHRI:Item 3990099045/7855
English  |  正體中文  |  简体中文  |  Items with full text/Total items : 12145/12927 (94%)
Visitors : 859546      Online Users : 644
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
    •  Adv. Search
    Home ‧ Login ‧ Upload ‧ Help ‧ About ‧ Administer Goto mobile version


    Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/7855


    Title: The epidemiology of gastrointestinal stromal tumors in Taiwan, 1998-2008: A nation-wide cancer registry-based study
    Authors: Chiang, NJ;Chen, LT;Tsai, CR;Chang, J
    Contributors: National Institute of Cancer Research
    Abstract: BACKGROUND:To investigate the incidence of gastrointestinal stromal tumors (GISTs) in Taiwan and the impact of imatinib on the overall survival (OS) of GIST patients.METHODS:GISTs were identified from the Taiwan Cancer Registry (TCR) from 1998 to 2008. The age-adjusted incidence rates and the observed OS rates were calculated. Cox proportional hazards models were applied to examine the mortality risk in three time periods (1998-2001, 2002-2004, 2005-2008) according to the application and availability of imatinib.RESULTS:From 1998 to 2008, 2,986 GISTs were diagnosed in Taiwan. The incidence increased from 1.13 per 100,000 in 1998 to 1.97 per 100,000 in 2008. The most common sites were stomach (47-59%), small intestine (31-38%), and colon/rectum (6-9%). The 5-year observed OS was 66.5% (60.3% for men, 74.2% for women, P<.0001). GISTs in the stomach had a better 5-year observed OS (69.4%) than those in the small intestine (65.1%) (P<.0001). The outcome of GIST improved significantly after the more widespread use of imatinib; the 5-year observed OS increased from 58.9% during 1998-2001 to 70.2% during 2005-2008 (P<.0001). Younger age, female sex, stomach location, and later diagnostic years were independent predictors of a better survival.CONCLUSIONS:The incidence of GIST has been increasing in Taiwan, partially due to the advancement of diagnostic technology/method and the increased awareness by physicians. The outcome of GIST has improved significantly with the availability and the wider use of imatinib.
    Date: 2014-02
    Relation: BMC Cancer. 2014 Feb 18;14:Article number 102.
    Link to: http://dx.doi.org/10.1186/1471-2407-14-102
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=1471-2407&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000332523500001
    Cited Times(Scopus): http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84894293730
    Appears in Collections:[Jeffrey Shu-Ming] Periodical Articles
    [Li-Tzong Chen] Periodical Articles
    [Nai-Jung Chiang] Periodical Articles

    Files in This Item:

    File Description SizeFormat
    BMC2014022501.pdf328KbAdobe PDF613View/Open


    All items in NHRI are protected by copyright, with all rights reserved.

    Related Items in TAIR

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback